Zynoviq Solutions
ZYNOVIQSOLUTIONS

PHARMACEUTICALS & BIOTECH

Reduce the $2.6 Billion Cost of Bringing a Drug to Market

Drug development averages $2.6 billion over 10-15 years with a 90% clinical trial failure rate. FDA warning letters halt production lines for months. Zynoviq accelerates R&D decisions, predicts manufacturing deviations, and automates GxP compliance across your entire operation.

The Challenge

90% Failure Rate, $2.6B Average Cost Per Drug

Pharmaceutical enterprises face unprecedented pressure from rising R&D costs, tightening regulatory scrutiny from FDA and EMA, manufacturing quality failures, and fragile global supply chains.

R&D Cost Escalation

Average drug development exceeds $2.6 billion over 10-15 years. Late-stage clinical trial failures destroy shareholder value and delay patient access to therapies.

$2.6B average cost per approved drug

Regulatory Compliance

FDA, EMA, and global health authorities demand validated systems, complete audit trails, 21 CFR Part 11 electronic records, and ICH Q8-Q12 quality-by-design compliance.

FDA warning letters increased 23% year-over-year

Manufacturing Deviations

Batch failures, deviation investigations, and CAPA management consume 30-40% of quality team capacity. Each batch failure costs $500K-$2M in lost product and investigation resources.

$500K-$2M cost per batch failure event

Cold Chain & Supply Risk

Temperature excursions destroy $35 billion in pharma products annually. API sourcing concentration and global distribution complexity create single-point-of-failure risks.

$35B in annual pharma product losses from cold chain failures

The Solution

Validated Intelligence for Regulated Environments

Zynoviq deploys as a 21 CFR Part 11-compliant platform with complete audit trails, validated workflows, and GxP-ready documentation from day one.

20% faster development decisions

R&D Decision Acceleration

Clinical trial analytics, literature mining, patent landscape analysis, and competitive intelligence to accelerate go/no-go decisions and reduce late-stage failure risk.

75% less manual documentation

GxP Compliance Engine

Automated 21 CFR Part 11 compliance, electronic batch records, deviation tracking, CAPA workflow management, and pre-built ICH Q8-Q12 quality-by-design templates.

35% fewer batch deviations

Manufacturing Quality Prediction

Process parameter monitoring, critical quality attribute prediction, and root cause analysis that identifies deviation triggers before they cause batch failures.

Real-time cold chain visibility

Supply Chain Intelligence

End-to-end supply chain monitoring, API supplier risk scoring, temperature excursion prediction, and demand forecasting for global distribution networks.

Compliance & Security

FDA 21 CFR Part 11 • EMA • ICH Q8-Q12 • GMP/GxP • SOC 2 Type II • On-Premise Deployment

Accelerate Drug Development, Not Risk

Leading pharmaceutical companies use Zynoviq to predict manufacturing deviations and automate GxP compliance. See the impact on your pipeline.